These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 29045188)

  • 1. RAPID EVOLUTION OF THYROID DYSFUNCTION IN PATIENTS TREATED WITH NIVOLUMAB.
    O'Malley G; Lee HJ; Parekh S; Galsky MD; Smith CB; Friedlander P; Yanagisawa RT; Gallagher EJ
    Endocr Pract; 2017 Oct; 23(10):1223-1231. PubMed ID: 29045188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study.
    Yamauchi I; Sakane Y; Fukuda Y; Fujii T; Taura D; Hirata M; Hirota K; Ueda Y; Kanai Y; Yamashita Y; Kondo E; Sone M; Yasoda A; Inagaki N
    Thyroid; 2017 Jul; 27(7):894-901. PubMed ID: 28537531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.
    Kotwal A; Kottschade L; Ryder M
    Thyroid; 2020 Feb; 30(2):177-184. PubMed ID: 31813343
    [No Abstract]   [Full Text] [Related]  

  • 4. Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab.
    Kimbara S; Fujiwara Y; Iwama S; Ohashi K; Kuchiba A; Arima H; Yamazaki N; Kitano S; Yamamoto N; Ohe Y
    Cancer Sci; 2018 Nov; 109(11):3583-3590. PubMed ID: 30230649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab.
    de Filette J; Jansen Y; Schreuer M; Everaert H; Velkeniers B; Neyns B; Bravenboer B
    J Clin Endocrinol Metab; 2016 Nov; 101(11):4431-4439. PubMed ID: 27571185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab.
    Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
    Tohoku J Exp Med; 2018 Jan; 244(1):33-40. PubMed ID: 29343652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BASELINE TSH LEVEL IS ASSOCIATED WITH RISK OF ANTI-PD-1-INDUCED THYROID DYSFUNCTION.
    Pollack RM; Kagan M; Lotem M; Dresner-Pollak R
    Endocr Pract; 2019 Aug; 25(8):824-829. PubMed ID: 31013164
    [No Abstract]   [Full Text] [Related]  

  • 8. Hypothyroidism in Cancer Patients on Immune Checkpoint Inhibitors with anti-PD1 Agents: Insights on Underlying Mechanisms.
    Alhusseini M; Samantray J
    Exp Clin Endocrinol Diabetes; 2017 Apr; 125(4):267-269. PubMed ID: 28073132
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunoassay Interference on Thyroid Function Tests During Treatment with Nivolumab.
    Paragliola RM; Corsello A; Papi G; Melfa E; Urbani A; Pontecorvi A; Corsello SM; Carrozza C
    Thyroid; 2020 Jul; 30(7):1091-1094. PubMed ID: 32122271
    [No Abstract]   [Full Text] [Related]  

  • 10. Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes.
    Peiró I; Palmero R; Iglesias P; Díez JJ; Simó-Servat A; Marín JA; Jiménez L; Domingo-Domenech E; Mancho-Fora N; Nadal E; Villabona C
    Endocrine; 2019 Jun; 64(3):605-613. PubMed ID: 30805887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer.
    Muir CA; Menzies AM; Clifton-Bligh R; Tsang VHM
    Thyroid; 2020 Oct; 30(10):1458-1469. PubMed ID: 32264785
    [No Abstract]   [Full Text] [Related]  

  • 12. Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors.
    Yoon JH; Hong AR; Kim HK; Kang HC
    Endocrinol Metab (Seoul); 2021 Apr; 36(2):413-423. PubMed ID: 33820396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nivolumab-induced Thyroid Dysfunctions in Patients with Previously Treated Non-small Cell Lung Cancer.
    Zhang X; Wu Y; Lv J; Li X; Ma L; Nong J; Zhang H; Qin N; Zhang Q; Shi G; Yang X; Wang J; Zhang S
    Interdiscip Sci; 2019 Jun; 11(2):287-291. PubMed ID: 31187431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Nivolumab-induced hypothyroidism: A case report].
    Lin C; Guo Z; Mo Z
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2019 Feb; 44(2):222-224. PubMed ID: 30837393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms.
    Delivanis DA; Gustafson MP; Bornschlegl S; Merten MM; Kottschade L; Withers S; Dietz AB; Ryder M
    J Clin Endocrinol Metab; 2017 Aug; 102(8):2770-2780. PubMed ID: 28609832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint inhibitor-related thyroid dysfunction.
    Iwama S; Kobayashi T; Yasuda Y; Arima H
    Best Pract Res Clin Endocrinol Metab; 2022 May; 36(3):101660. PubMed ID: 35501263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive Factors of Nivolumab-induced Hypothyroidism in Patients with Non-small Cell Lung Cancer.
    Maekura T; Naito M; Tahara M; Ikegami N; Kimura Y; Sonobe S; Kobayashi T; Tsuji T; Minomo S; Tamiya A; Atagi S
    In Vivo; 2017; 31(5):1035-1039. PubMed ID: 28882978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab.
    Yamauchi I; Yasoda A; Matsumoto S; Sakamori Y; Kim YH; Nomura M; Otsuka A; Yamasaki T; Saito R; Kitamura M; Kitawaki T; Hishizawa M; Kawaguchi-Sakita N; Fujii T; Taura D; Sone M; Inagaki N
    PLoS One; 2019; 14(5):e0216954. PubMed ID: 31086392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nivolumab-induced thyroid dysfunction lacking antithyroid antibody is frequently evoked in Japanese patients with malignant melanoma.
    Yano S; Ashida K; Nagata H; Ohe K; Wada N; Takeichi Y; Hanada Y; Ibayashi Y; Wang L; Sakamoto S; Sakamoto R; Uchi H; Shiratsuchi M; Furue M; Nomura M; Ogawa Y
    BMC Endocr Disord; 2018 Jun; 18(1):36. PubMed ID: 29884162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors.
    Mazarico I; Capel I; Giménez-Palop O; Albert L; Berges I; Luchtenberg F; García Y; Fernández-Morales LA; De Pedro VJ; Caixàs A; Rigla M
    J Endocrinol Invest; 2019 Dec; 42(12):1443-1450. PubMed ID: 31093955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.